[HTML][HTML] Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in older residents of a long-term care facility: relation with age, frailty and prior infection status

P Seiffert, A Konka, J Kasperczyk, J Kawa, M Lejawa… - Biogerontology, 2022 - Springer
Clinical and biological assessment of the COVID-19 vaccine efficacy in the frail population is
of crucial importance. The study focuses on measuring the levels of anti-SARS-CoV-2 IgG …

Antibody response 3 months after 2 doses of BNT162b2 mRNA COVID-19 vaccine in residents of long-term care facilities

R Causa, D Almagro-Nievas, M Rivera-Izquierdo… - Gerontology, 2022 - karger.com
Background: Older adults living in long-term care facilities (LTCFs) are at increased risk for
severe outcomes from COVID-19 and were identified as a priority group in COVID-19 …

Characterization of the humoral immune response to BNT162b2 in elderly residents of long-term care facilities five to seven months after vaccination

M Delbrück, S Hoehl, T Toptan, B Schenk, K Grikscheit… - medrxiv, 2021 - medrxiv.org
The elderly residing in long-term care facilities (LTCFs) are a group at high risk for COVID-
19. Hence, monitoring of the vaccine-based immunity has a pivotal role in identifying …

Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities

M Trigueros, E Pradenas, D Palacín… - Age and …, 2022 - academic.oup.com
Background SARS-CoV-2 vaccination is the most effective strategy to protect older residents
of long-term care facilities (LTCF) against severe COVID-19, but primary vaccine responses …

[HTML][HTML] Humoral and cellular responses to COVID-19 vaccination indicate the need for post-vaccination testing in frail population

W Witkowski, S Gerlo, E De Smet, M Wejda, D Acar… - Vaccines, 2022 - mdpi.com
Despite the high efficacy of the BNT162b2 vaccine in the general population, data on its
immunogenicity among frail elderly individuals are limited. Recently, levels of anti-SARS …

[HTML][HTML] Humoral and Cellular Immune Response Elicited by the BNT162b2 COVID-19 Vaccine Booster in Elderly

D Dalla Gasperina, G Veronesi, CM Castelletti… - International Journal of …, 2023 - mdpi.com
Although the safety and efficacy of COVID-19 vaccines in older people are critical to their
success, little is known about their immunogenicity among elderly residents of long-term …

BNT162b2 mRNA COVID-19 (Comirnaty) vaccine effectiveness in elderly patients who live in long-term care facilities: a nationwide cohort

S Goldin, L Adler, J Azuri, L Mendel, S Haviv… - Gerontology, 2022 - karger.com
Introduction: In early 2020, the novel SARS-CoV-2 virus began to spread around the world
and claim victims. Initially, in the Western world, COVID-19-related mortality was due to …

[HTML][HTML] Impaired functional T-cell response to SARS-CoV-2 after two doses of BNT162b2 mRNA vaccine in older people

J Demaret, B Corroyer-Simovic, EK Alidjinou… - Frontiers in …, 2021 - frontiersin.org
Long-term care facility (LTCF) older residents display physiological alterations of cellular
and humoral immunity that affect vaccine responses. Preliminary reports suggested a low …

Immunogenicity of the BNT162b2 vaccine in frail or disabled nursing home residents: COVID‐A study

S Salmerón Ríos, M Mas Romero… - Journal of the …, 2021 - Wiley Online Library
Abstract Background/Objectives The safety and immunogenicity of the BNT162b2
coronavirus disease 2019 (COVID‐19) vaccine in older adults with different frailty and …

Immunogenicity after 6 months of BNT162b2 vaccination in frail or disabled nursing home residents: The COVID‐A Study

S Salmeron Rios, EB Cortés Zamora… - Journal of the …, 2022 - Wiley Online Library
Background There is incomplete information regarding evolution of antibody titers against
SARS‐CoV‐2 after a two‐dose strategy vaccination with BNT162b2 in older adults in long …